• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

极端和泛耐药细菌导致额外死亡:是神话还是现实?

Extremely and pandrug-resistant bacteria extra-deaths: myth or reality?

机构信息

IRD, MEPHI, AP-HM, IHU-Méditerranée-Infection, Aix-Marseille University, Marseille, France.

IRD, VITROME, AP-HM, SSA, IHU-Méditerranée-Infection, Aix-Marseille University, Marseille, France.

出版信息

Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1687-1697. doi: 10.1007/s10096-018-3300-0. Epub 2018 Jun 28.

DOI:10.1007/s10096-018-3300-0
PMID:29956024
Abstract

In 2009, the European Centre for Disease Prevention and Control (ECDC) estimated that multidrug-resistant (MDR) bacterial infections were responsible for 25,000 extra-deaths per year. In 2015, another report estimated that 12,500 extra-deaths were attributable to MDR bacteria every year in France. Recently, the United Nations claimed that resistance to antimicrobials was a global scourge, forecasting 10 million deaths in 2050. Surprisingly, our antibiotic resistance surveillance system in Marseille, France, did not allowed us to observe similar trends. We herein compared our data on extremely drug-resistant (XDR)/pandrug-resistant (PDR) patient extra-deaths to evaluations and predictions from these reports. First, we retrospectively collect and analyze antibiotic resistance data produced by our settings between November 2009 and March 2015 to look for 30-day deaths attributable to XDR/PDR strains belonging to 11 bacterial species/genus. In parallel, we performed a PubMed literature search to look for articles published prior to July 2016 and describing human deaths due to PDR strains. Overall, 35,723 patients were infected by at least one bacterial species/genus of interest and 85 by XDR/PDR strains. Of these patients, only one death was attributable to a XDR bacterial infection in a patient with strong comorbidities and two consecutive septic shocks. Our literature review shows that only four articles described human deaths due to PDR bacteria. All together, these data allowed us to conclude that there is a large discrepancy between the real count of deaths attributable to XDR/PDR bacteria and alarmist predictions.

摘要

2009 年,欧洲疾病预防控制中心(ECDC)估计,每年有 25000 例额外死亡是由多药耐药(MDR)细菌感染引起的。2015 年,另一份报告估计,法国每年有 12500 例额外死亡归因于 MDR 细菌。最近,联合国声称,对抗生素的耐药性是一个全球性的祸害,并预测到 2050 年将有 1000 万人死亡。令人惊讶的是,我们在法国马赛的抗生素耐药性监测系统却无法观察到类似的趋势。我们在此将我们对极度耐药(XDR)/泛耐药(PDR)患者额外死亡的数据与这些报告的评估和预测进行了比较。首先,我们回顾性地收集和分析了我们在 2009 年 11 月至 2015 年 3 月期间的数据,以寻找 30 天内归因于属于 11 种细菌/属的 XDR/PDR 菌株的死亡。同时,我们进行了PubMed 文献检索,以寻找 2016 年 7 月之前发表的描述因 PDR 菌株导致人类死亡的文章。总的来说,有 35723 名患者被至少一种感兴趣的细菌/属感染,有 85 名患者被 XDR/PDR 菌株感染。在这些患者中,只有一名患有严重合并症且连续发生两次感染性休克的 XDR 细菌感染者死亡。我们的文献回顾显示,只有四篇文章描述了因 PDR 细菌导致的人类死亡。总的来说,这些数据使我们得出结论,XDR/PDR 细菌导致的实际死亡人数与危言耸听的预测之间存在很大差距。

相似文献

1
Extremely and pandrug-resistant bacteria extra-deaths: myth or reality?极端和泛耐药细菌导致额外死亡:是神话还是现实?
Eur J Clin Microbiol Infect Dis. 2018 Sep;37(9):1687-1697. doi: 10.1007/s10096-018-3300-0. Epub 2018 Jun 28.
2
Evaluating the Clinical Burden and Mortality Attributable to Antibiotic Resistance: The Disparity of Empirical Data and Simple Model Estimations.评估抗生素耐药性的临床负担和死亡率:经验数据与简单模型估计的差异。
Clin Infect Dis. 2017 Aug 15;65(suppl_1):S58-S63. doi: 10.1093/cid/cix346.
3
Infections due to multidrug-resistant organisms following heart transplantation: Epidemiology, microbiology, and outcomes.心脏移植后多重耐药菌感染:流行病学、微生物学及预后
Transpl Infect Dis. 2020 Feb;22(1):e13215. doi: 10.1111/tid.13215. Epub 2019 Dec 12.
4
The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey.多重耐药感染的传播导致肝硬化患者经验性抗生素治疗失败率上升:一项前瞻性调查。
PLoS One. 2015 May 21;10(5):e0127448. doi: 10.1371/journal.pone.0127448. eCollection 2015.
5
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.耐多药、广泛耐药和全耐药细菌:获得性耐药的国际专家临时标准定义建议
Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27.
6
Do we need new antibiotics?我们是否需要新的抗生素?
Clin Microbiol Infect. 2016 May;22(5):408-15. doi: 10.1016/j.cmi.2016.03.012. Epub 2016 Mar 26.
7
Risk factors of multidrug-resistant, extensively drug-resistant and pandrug-resistant Acinetobacter baumannii ventilator-associated pneumonia in a Medical Intensive Care Unit of University Hospital in Thailand.泰国某大学医院医学重症监护病房中多重耐药、广泛耐药及泛耐药鲍曼不动杆菌呼吸机相关性肺炎的危险因素
J Infect Chemother. 2015 Aug;21(8):570-4. doi: 10.1016/j.jiac.2015.04.010. Epub 2015 May 7.
8
Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.重症监护病房感染泛耐药和广泛耐药碳青霉烯酶-producing 革兰氏阴性菌的患者使用磷霉素治疗的结果。
Int J Antimicrob Agents. 2014 Jan;43(1):52-9. doi: 10.1016/j.ijantimicag.2013.09.010. Epub 2013 Oct 16.
9
No global increase in resistance to antibiotics: a snapshot of resistance from 2001 to 2016 in Marseille, France.未发现全球抗生素耐药性增加:法国马赛 2001 至 2016 年耐药性快照。
Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):395-407. doi: 10.1007/s10096-018-3439-8. Epub 2018 Dec 4.
10
Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria.泛耐药革兰氏阴性菌感染的结局
BMC Infect Dis. 2005 Apr 8;5:24. doi: 10.1186/1471-2334-5-24.

引用本文的文献

1
Innovation in the Design of Clinical Trials for Infectious Diseases: Focusing on Patients Over Pathogens.传染病临床试验设计的创新:以患者而非病原体为重点。
Pharmaceut Med. 2025 Mar;39(2):73-86. doi: 10.1007/s40290-025-00552-3. Epub 2025 Mar 12.
2
Demographics, epidemiology, mortality and difficult-to-treat resistance patterns of bacterial bloodstream infections in the global US Military Health System from 2010 to 2019: a retrospective cohort study.2010年至2019年全球美国军事卫生系统中细菌性血流感染的人口统计学、流行病学、死亡率及难治性耐药模式:一项回顾性队列研究
BMJ Open. 2025 Mar 3;15(3):e094861. doi: 10.1136/bmjopen-2024-094861.
3

本文引用的文献

1
Bacteraemia due to extensively drug-resistant Pseudomonas aeruginosa sequence type 235 high-risk clone: Facing the perfect storm.广泛耐药铜绿假单胞菌 235 型高危克隆引起的菌血症:直面完美风暴。
Int J Antimicrob Agents. 2018 Aug;52(2):172-179. doi: 10.1016/j.ijantimicag.2018.03.018. Epub 2018 Apr 3.
2
Are we living in an antibiotic resistance nightmare?我们生活在抗生素耐药性的噩梦中吗?
Clin Microbiol Infect. 2018 Jun;24(6):568-569. doi: 10.1016/j.cmi.2018.01.004. Epub 2018 Jan 11.
3
New Approaches to Prevent Healthcare-Associated Infection.
Demographics, Epidemiology, Mortality, and Difficult-To-Treat Resistance Patterns of Bacterial Bloodstream Infections in the Global United States Military Health System from 2010-2019: A Retrospective Cohort Study.
2010 - 2019年全球美国军事卫生系统中细菌性血流感染的人口统计学、流行病学、死亡率及难治性耐药模式:一项回顾性队列研究
medRxiv. 2024 Oct 3:2024.10.02.24314780. doi: 10.1101/2024.10.02.24314780.
4
6-Aza-2-Thiothymine-Capped Gold Nanoclusters as Robust Antimicrobial Nanoagents for Eradicating Multidrug-Resistant Infection.6-氮杂-2-硫代胸腺嘧啶封端的金纳米团簇作为用于根除多重耐药感染的强效抗菌纳米剂
ACS Omega. 2023 Nov 28;8(49):47123-47133. doi: 10.1021/acsomega.3c07114. eCollection 2023 Dec 12.
5
Staph wars: the antibiotic pipeline strikes back.葡萄球菌之战:抗生素管道奋起反击。
Microbiology (Reading). 2023 Sep;169(9). doi: 10.1099/mic.0.001387.
6
Secondary bacterial infections & extensively drug-resistant bacteria among COVID-19 hospitalized patients at the University Hospital in Kraków.克拉科夫大学医院 COVID-19 住院患者中的继发性细菌感染和广泛耐药菌。
Ann Clin Microbiol Antimicrob. 2023 Aug 24;22(1):77. doi: 10.1186/s12941-023-00625-8.
7
The prevalence of colistin resistance in clinical Stenotrophomonas maltophilia isolates worldwide: a systematic review and meta-analysis.全球临床嗜麦芽寡养单胞菌分离株中多粘菌素耐药的流行情况:系统评价和荟萃分析。
BMC Microbiol. 2023 Jul 28;23(1):200. doi: 10.1186/s12866-023-02950-6.
8
Antimicrobial Resistance in the Global Health Network: Known Unknowns and Challenges for Efficient Responses in the 21st Century.全球卫生网络中的抗菌素耐药性:21世纪已知的未知因素及有效应对挑战
Microorganisms. 2023 Apr 17;11(4):1050. doi: 10.3390/microorganisms11041050.
9
Metagenome data-based phage therapy for intestinal bacteria-mediated diseases.基于宏基因组数据的噬菌体疗法治疗肠道细菌介导的疾病。
Biosci Microbiota Food Health. 2023;42(1):8-12. doi: 10.12938/bmfh.2022-061. Epub 2022 Oct 5.
10
Phage therapy for infection.噬菌体疗法治疗 感染。
Front Immunol. 2022 Oct 28;13:1057892. doi: 10.3389/fimmu.2022.1057892. eCollection 2022.
预防医源性感染的新方法。
Clin Infect Dis. 2017 Aug 15;65(suppl_1):S50-S54. doi: 10.1093/cid/cix433.
4
From Expert Protocols to Standardized Management of Infectious Diseases.从专家方案到传染病的标准化管理。
Clin Infect Dis. 2017 Aug 15;65(suppl_1):S12-S19. doi: 10.1093/cid/cix403.
5
Evaluating the Clinical Burden and Mortality Attributable to Antibiotic Resistance: The Disparity of Empirical Data and Simple Model Estimations.评估抗生素耐药性的临床负担和死亡率:经验数据与简单模型估计的差异。
Clin Infect Dis. 2017 Aug 15;65(suppl_1):S58-S63. doi: 10.1093/cid/cix346.
6
Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050?到2050年,每年会有1000万人死于抗微生物药物耐药性吗?
PLoS Med. 2016 Nov 29;13(11):e1002184. doi: 10.1371/journal.pmed.1002184. eCollection 2016 Nov.
7
Forgotten antibiotics: a follow-up inventory study in Europe, the USA, Canada and Australia.被遗忘的抗生素:在欧洲、美国、加拿大和澳大利亚的一项后续库存研究。
Int J Antimicrob Agents. 2017 Jan;49(1):98-101. doi: 10.1016/j.ijantimicag.2016.09.029. Epub 2016 Nov 16.
8
Ten key points for the appropriate use of antibiotics in hospitalised patients: a consensus from the Antimicrobial Stewardship and Resistance Working Groups of the International Society of Chemotherapy.住院患者抗生素合理应用的 10 个要点:国际化疗学会抗菌药物管理和耐药性工作组的共识。
Int J Antimicrob Agents. 2016 Sep;48(3):239-46. doi: 10.1016/j.ijantimicag.2016.06.015. Epub 2016 Jul 25.
9
Escherichia coli Harboring mcr-1 and blaCTX-M on a Novel IncF Plasmid: First Report of mcr-1 in the United States.携带新型IncF质粒上mcr - 1和blaCTX - M的大肠杆菌:美国mcr - 1的首次报道
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4420-1. doi: 10.1128/AAC.01103-16. Print 2016 Jul.
10
Do we need new antibiotics?我们是否需要新的抗生素?
Clin Microbiol Infect. 2016 May;22(5):408-15. doi: 10.1016/j.cmi.2016.03.012. Epub 2016 Mar 26.